Echelon Wealth Partners analyst Douglas Loe maintained a Buy rating on Cipher Pharmaceuticals (CPHRF) yesterday and set a price target of C$4.00. The company’s shares closed last Monday at $0.86.
According to TipRanks.com, Loe is a 4-star analyst with an average return of 7.8% and a 43.1% success rate. Loe covers the Healthcare sector, focusing on stocks such as Neptune Wellness Solutions, IntelGenx Technologies, and Liminal BioSciences.
Cipher Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.08.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.52 and a one-year low of $0.67. Currently, Cipher Pharmaceuticals has an average volume of 2,016.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products.